



Jazz Pharmaceuticals to Announce 2011 Full Year and Fourth Quarter Financial Results on February 27, 2012

February 14, 2012

DUBLIN, Feb. 14, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a conference call and live webcast on Monday, February 27, 2011 at 4:30 p.m. EST/9:30 p.m. GMT. During the call, company management will provide a business update and review fourth quarter and full year 2011 financial results.

The live webcast and press release may be accessed from the Investors section of the Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archived version of the webcast will be available for at least one week.

Investors may participate in the conference call by dialing 1-888-396-2356 in the U.S., or +1-617-847-8709 outside the U.S., and entering passcode 70752389.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women's health. The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%).

SOURCE Jazz Pharmaceuticals plc

Ami Knoefler, Executive Director, Investor Relations & Corporate Communications, Jazz Pharmaceuticals plc, Ireland, + 353 1 638 1032, U.S., +1-650-496-2947